Business Description
Cullinan Oncology Inc
NAICS : 541713
SIC : 2834
Share Class Description:
CGEM: Ordinary SharesDescription
Cullinan Oncology Inc is a biopharmaceutical company. It is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 78.42 | |||||
| Equity-to-Asset | 0.96 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.04 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -13.4 | |||||
| 3-Year FCF Growth Rate | -14.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 26.07 | |||||
| 9-Day RSI | 32.49 | |||||
| 14-Day RSI | 36.32 | |||||
| 6-1 Month Momentum % | 1.3 | |||||
| 12-1 Month Momentum % | -12.38 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 25.32 | |||||
| Quick Ratio | 25.32 | |||||
| Cash Ratio | 24.99 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -58.7 | |||||
| Shareholder Yield % | -0.89 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -26.15 | |||||
| ROA % | -24.59 | |||||
| ROIC % | -231.14 | |||||
| ROC (Joel Greenblatt) % | -3796.01 | |||||
| ROCE % | -29.86 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.77 | |||||
| Price-to-Tangible-Book | 0.77 | |||||
| EV-to-EBIT | 0.61 | |||||
| EV-to-EBITDA | 0.61 | |||||
| EV-to-Forward-Revenue | 1.06 | |||||
| EV-to-FCF | 0.61 | |||||
| Price-to-Net-Current-Asset-Value | 0.81 | |||||
| Price-to-Net-Cash | 0.82 | |||||
| Earnings Yield (Greenblatt) % | 163.93 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CGEM
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cullinan Oncology Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -3.37 | ||
| Beta | 0 | ||
| Volatility % | 24.08 | ||
| 14-Day RSI | 36.32 | ||
| 14-Day ATR ($) | 0.53957 | ||
| 20-Day SMA ($) | 10.1085 | ||
| 12-1 Month Momentum % | -12.38 | ||
| 52-Week Range ($) | 7.782 - 13.985 | ||
| Shares Outstanding (Mil) | 42.73 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cullinan Oncology Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cullinan Oncology Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cullinan Oncology Inc Frequently Asked Questions
What is Cullinan Oncology Inc(CGEM)'s stock price today?
The current price of CGEM is $9.05. The 52 week high of CGEM is $13.99 and 52 week low is $7.78.
When is next earnings date of Cullinan Oncology Inc(CGEM)?
The next earnings date of Cullinan Oncology Inc(CGEM) is 2023-11-14 Est..
Does Cullinan Oncology Inc(CGEM) pay dividends? If so, how much?
Cullinan Oncology Inc(CGEM) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers